04:18 AM EDT, 05/13/2024 (MT Newswires) -- Qiagen ( QGEN ) said Monday the US Food and Drug Administration has cleared its QIAstat-Dx Respiratory Panel Plus syndromic test for clinical use.

The test is designed to help diagnose viral and bacterial upper respiratory infections. It was already granted FDA Emergency Use Authorization to detect the virus that causes COVID-19, the company said.

Price: 43.61, Change: +0.01, Percent Change: +0.02